TRANSCENTA-B (06628) is planning to discount approximately 18.76% to distribute 14.4 million shares, with a net raise of about HK$59.34 million.

TRANSCENTA-B (06628) announced on September 10, 2025, that the company plans to offer 14.4 million shares, representing approximately 3.20% of the total number of shares issued after the completion of the offering (excluding treasury shares). The offering price is 4.33 Hong Kong dollars per share, representing a discount of approximately 18.76% compared to the closing price of 5.33 Hong Kong dollars per share on September 9. The expected total proceeds from the offering are approximately 62.35 million Hong Kong dollars, with net proceeds of approximately 59.34 million Hong Kong dollars. The company plans to allocate the net proceeds from the subscription as follows: (i) 40% for the clinical development of pipeline assets such as TST001 and TST002; (ii) 30% for advancing promising pipeline assets with near-term licensing potential, including TST801, TST013, and TST786; (iii) 30% for working capital and general purposes to enhance the company's financial stability, including but not limited to general business operations and business development.